{"id":{"repo_id":"uiuc","oai_identifier":"oai:www.ideals.illinois.edu:2142/101261"},"canonical_url":"https://search.dev.ndltd.org/etd/uiuc/oai:www.ideals.illinois.edu:2142/101261","repository":{"repo_id":"uiuc","name":"University of Illinois - Urbana-Champaign","base_url":"https://www.ideals.illinois.edu/oai-pmh"},"display":{"title":"Synthesis, biological activity and mechanism of atypical carotenoid antilipoperoxidants","abstract":"Lipid peroxidation has long been correlated to and proposed to be a causative factor in a myriad of human diseases. However, identifying a causative mechanistic role of lipid peroxidation has proven challenging and the role of oxidized lipids in disease pathogenesis remains enigmatic. We posited that a potent small molecule inhibitor of lipid peroxidation could be a useful probe to understand the role of lipid peroxidation in human disease. Carotenoids are an extensively studied class of polyene containing small molecules with antilipoperoxidant activity. Yet no significant progress has been made towards utilizing carotenoids either as clinically proven treatments or to definitively probe the role of lipid peroxidation in disease pathogenesis. We therefore sought to identify an exceptionally potent small molecule inhibitor of bilayer lipid peroxidation to advance our understanding of the specific role(s) this process plays in disease pathogenesis. Additionally, such a molecule could serve as a starting point for the development of small molecule replacements for missing or dysfunctional antilipoperoxidant proteins. We questioned whether environmental pressures might have driven the evolution of exceptional natural product antilipoperoxidants in microorganisms that thrive in environments of extreme oxidative stress. We specifically sought to characterize the antilipoperoxidant activity of three highly atypical carotenoids, peridinin, synechoxanthin, and chlamydaxanthin. We synthesized each of these natural products utilizing an efficient and modular building block based approach. This strategy allowed for initial activity assays as well synthesis of isotopically labeled carotenoids and scale-up for animal experiments. We found that the atypical carotenoid peridinin is an exceptionally potent inhibitor of non-enzymatic bilayer lipid peroxidation in both chemically defined liposomes and primary human endothelial cells. Mechanistic investigation showed, as compared to astaxanthin, peridinin does not act through inhibition of lipid lateral diffusion nor does it have a higher inherent rate of radical quenching activity. SSNMR experiments with a synthesized isotopologue showed that the increased potency of peridinin is due to its increased propensity to embed within the lipid bilayer. That is, in contrast to the primarily extramembranous localization of the widely used but much less potent antilipoperoxidant astaxanthin, peridinin is completely embedded within and physically spans the hydrophobic core of POPC membranes, maximizing its concentration at the site of the targeted lipid peroxidation reactions. In a final set of experiments, we utilized peridinin to probe the role of lipid peroxidation in atherosclerosis and asthma. In primary human endothelial cells, we found that small molecule-mediated inhibition of bilayer lipid peroxidation blocks stress-induced monocyte-endothelial cell adhesion, a key step in atherogenesis. In contrast, in two different mouse models of acute asthma, our preliminary results suggest that lipid peroxidation does not drive the pathogenesis of asthma. We did not observe a consistent increase in oxidized lipids in these models, nor did peridinin have any measurable effect on the asthmatic phenotype. Further studies are required to understand the biodistribution of peridinin and evaluate lipid peroxidation in clinically relevant chronic mouse models of asthma. In conclusion, we have identified peridinin as a potent and membrane embedded inhibitor of lipid peroxidation with the potential to further probe the role of lipid peroxidation in a multitude of human diseases.","abstract_html":"Lipid peroxidation has long been correlated to and proposed to be a causative factor in a myriad of human diseases. However, identifying a causative mechanistic role of lipid peroxidation has proven challenging and the role of oxidized lipids in disease pathogenesis remains enigmatic. We posited that a potent small molecule inhibitor of lipid peroxidation could be a useful probe to understand the role of lipid peroxidation in human disease. Carotenoids are an extensively studied class of polyene containing small molecules with antilipoperoxidant activity. Yet no significant progress has been made towards utilizing carotenoids either as clinically proven treatments or to definitively probe the role of lipid peroxidation in disease pathogenesis. We therefore sought to identify an exceptionally potent small molecule inhibitor of bilayer lipid peroxidation to advance our understanding of the specific role(s) this process plays in disease pathogenesis. Additionally, such a molecule could serve as a starting point for the development of small molecule replacements for missing or dysfunctional antilipoperoxidant proteins. We questioned whether environmental pressures might have driven the evolution of exceptional natural product antilipoperoxidants in microorganisms that thrive in environments of extreme oxidative stress. We specifically sought to characterize the antilipoperoxidant activity of three highly atypical carotenoids, peridinin, synechoxanthin, and chlamydaxanthin. We synthesized each of these natural products utilizing an efficient and modular building block based approach. This strategy allowed for initial activity assays as well synthesis of isotopically labeled carotenoids and scale-up for animal experiments. We found that the atypical carotenoid peridinin is an exceptionally potent inhibitor of non-enzymatic bilayer lipid peroxidation in both chemically defined liposomes and primary human endothelial cells. Mechanistic investigation showed, as compared to astaxanthin, peridinin does not act through inhibition of lipid lateral diffusion nor does it have a higher inherent rate of radical quenching activity. SSNMR experiments with a synthesized isotopologue showed that the increased potency of peridinin is due to its increased propensity to embed within the lipid bilayer. That is, in contrast to the primarily extramembranous localization of the widely used but much less potent antilipoperoxidant astaxanthin, peridinin is completely embedded within and physically spans the hydrophobic core of POPC membranes, maximizing its concentration at the site of the targeted lipid peroxidation reactions. In a final set of experiments, we utilized peridinin to probe the role of lipid peroxidation in atherosclerosis and asthma. In primary human endothelial cells, we found that small molecule-mediated inhibition of bilayer lipid peroxidation blocks stress-induced monocyte-endothelial cell adhesion, a key step in atherogenesis. In contrast, in two different mouse models of acute asthma, our preliminary results suggest that lipid peroxidation does not drive the pathogenesis of asthma. We did not observe a consistent increase in oxidized lipids in these models, nor did peridinin have any measurable effect on the asthmatic phenotype. Further studies are required to understand the biodistribution of peridinin and evaluate lipid peroxidation in clinically relevant chronic mouse models of asthma. In conclusion, we have identified peridinin as a potent and membrane embedded inhibitor of lipid peroxidation with the potential to further probe the role of lipid peroxidation in a multitude of human diseases.","abstract_has_math":false,"creators":["Hill, Adam Greschek"],"institution":"University of Illinois at Urbana-Champaign","degree_name":"Ph.D.","degree_level":"Dissertation","degree_discipline":"Chemistry","degree_department":null,"school":null,"contributors":["Burke, Martin D.","Mitchell, Douglas A.","Zimmerman, Steven C.","Imlay, James A."],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2018,"date_issued":"2018-09-04T20:46:49Z","date_published":"2018-09-04T20:46:49Z","updated_at":"2026-07-22T22:24:38Z","subjects":["Chemistry","Biology","Chemical Biology","Lipid Oxidation","Antilipoperoxidant","Carotenoid","Natural Products","Solid-State Nuclear Magnetic Resonance","Atherosclerosis","Asthma","Astaxanthin","Chlamydaxanthin","Peridinin"],"languages":["en"],"rights":["Copyright 2018 Adam Greschek Hill"],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/2142/101261","outbound_label":"Handle","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Burke, Martin D.","Mitchell, Douglas A.","Zimmerman, Steven C.","Imlay, James A."]},{"key":"dc:creator","label":"Author","values":["Hill, Adam Greschek"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2018-09-04T20:46:49Z","2020-09-05T09:15:09Z","2018-03-13","2018-05"]},{"key":"dc:type","label":"Dc Type","values":["text"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Chemistry"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Ph.D."]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["University of Illinois at Urbana-Champaign"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Chemistry","Biology","Chemical Biology","Lipid Oxidation","Antilipoperoxidant","Carotenoid","Natural Products","Solid-State Nuclear Magnetic Resonance","Atherosclerosis","Asthma","Astaxanthin","Chlamydaxanthin","Peridinin"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["en"]},{"key":"dc:rights","label":"Dc Rights","values":["Copyright 2018 Adam Greschek Hill"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["http://hdl.handle.net/2142/101261"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Lipid peroxidation has long been correlated to and proposed to be a causative factor in a myriad of human diseases. However, identifying a causative mechanistic role of lipid peroxidation has proven challenging and the role of oxidized lipids in disease pathogenesis remains enigmatic. We posited that a potent small molecule inhibitor of lipid peroxidation could be a useful probe to understand the role of lipid peroxidation in human disease. Carotenoids are an extensively studied class of polyene containing small molecules with antilipoperoxidant activity. Yet no significant progress has been made towards utilizing carotenoids either as clinically proven treatments or to definitively probe the role of lipid peroxidation in disease pathogenesis. We therefore sought to identify an exceptionally potent small molecule inhibitor of bilayer lipid peroxidation to advance our understanding of the specific role(s) this process plays in disease pathogenesis. Additionally, such a molecule could serve as a starting point for the development of small molecule replacements for missing or dysfunctional antilipoperoxidant proteins. We questioned whether environmental pressures might have driven the evolution of exceptional natural product antilipoperoxidants in microorganisms that thrive in environments of extreme oxidative stress. We specifically sought to characterize the antilipoperoxidant activity of three highly atypical carotenoids, peridinin, synechoxanthin, and chlamydaxanthin. We synthesized each of these natural products utilizing an efficient and modular building block based approach. This strategy allowed for initial activity assays as well synthesis of isotopically labeled carotenoids and scale-up for animal experiments. We found that the atypical carotenoid peridinin is an exceptionally potent inhibitor of non-enzymatic bilayer lipid peroxidation in both chemically defined liposomes and primary human endothelial cells. Mechanistic investigation showed, as compared to astaxanthin, peridinin does not act through inhibition of lipid lateral diffusion nor does it have a higher inherent rate of radical quenching activity. SSNMR experiments with a synthesized isotopologue showed that the increased potency of peridinin is due to its increased propensity to embed within the lipid bilayer. That is, in contrast to the primarily extramembranous localization of the widely used but much less potent antilipoperoxidant astaxanthin, peridinin is completely embedded within and physically spans the hydrophobic core of POPC membranes, maximizing its concentration at the site of the targeted lipid peroxidation reactions. In a final set of experiments, we utilized peridinin to probe the role of lipid peroxidation in atherosclerosis and asthma. In primary human endothelial cells, we found that small molecule-mediated inhibition of bilayer lipid peroxidation blocks stress-induced monocyte-endothelial cell adhesion, a key step in atherogenesis. In contrast, in two different mouse models of acute asthma, our preliminary results suggest that lipid peroxidation does not drive the pathogenesis of asthma. We did not observe a consistent increase in oxidized lipids in these models, nor did peridinin have any measurable effect on the asthmatic phenotype. Further studies are required to understand the biodistribution of peridinin and evaluate lipid peroxidation in clinically relevant chronic mouse models of asthma. In conclusion, we have identified peridinin as a potent and membrane embedded inhibitor of lipid peroxidation with the potential to further probe the role of lipid peroxidation in a multitude of human diseases.","Submission published under a 24 month embargo labeled 'Closed Access', the embargo will last until 2020-05-01","The student, Adam Hill, accepted the attached license on 2018-03-13 at 09:06.","The student, Adam Hill, submitted this Dissertation for approval on 2018-03-13 at 09:33.","This Dissertation was approved for publication on 2018-03-13 at 16:47.","DSpace SAF Submission Ingestion Package generated from Vireo submission #12065 on 2018-08-31 at 17:25:14","Made available in DSpace on 2018-09-04T20:46:49Z (GMT). No. of bitstreams: 3 HILL-DISSERTATION-2018.pdf: 33224807 bytes, checksum: aefef5d4dd2153d62f8ec5f57e05872a (MD5) LICENSE.txt: 4206 bytes, checksum: ef6ce7874d42f876b15701ea24a4ee34 (MD5) PROQUEST_LICENSE.txt: 4552 bytes, checksum: d39fecade28b5022914a46809f86d527 (MD5) Previous issue date: 2018-03-13","Embargo set by: Seth Robbins for item 107346 Lift date: 2020-09-04T20:47:38Z Reason: Author requested closed access (OA after 2yrs) in Vireo ETD system","Embargo set by: Seth Robbins for item 107346 Lift date: 2020-09-04T20:50:11Z Reason: Author requested closed access (OA after 2yrs) in Vireo ETD system","Limited Restriction Lifted for Item 107346 on 2020-09-05T09:15:09Z."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dc:title","label":"Title","values":["Synthesis, biological activity and mechanism of atypical carotenoid antilipoperoxidants"]}]}],"canonical_facts":{"dc:contributor":["Burke, Martin D.","Mitchell, Douglas A.","Zimmerman, Steven C.","Imlay, James A."],"dc:creator":["Hill, Adam Greschek"],"dc:date":["2018-09-04T20:46:49Z","2020-09-05T09:15:09Z","2018-03-13","2018-05"],"dc:description":["Lipid peroxidation has long been correlated to and proposed to be a causative factor in a myriad of human diseases. However, identifying a causative mechanistic role of lipid peroxidation has proven challenging and the role of oxidized lipids in disease pathogenesis remains enigmatic. We posited that a potent small molecule inhibitor of lipid peroxidation could be a useful probe to understand the role of lipid peroxidation in human disease. Carotenoids are an extensively studied class of polyene containing small molecules with antilipoperoxidant activity. Yet no significant progress has been made towards utilizing carotenoids either as clinically proven treatments or to definitively probe the role of lipid peroxidation in disease pathogenesis. We therefore sought to identify an exceptionally potent small molecule inhibitor of bilayer lipid peroxidation to advance our understanding of the specific role(s) this process plays in disease pathogenesis. Additionally, such a molecule could serve as a starting point for the development of small molecule replacements for missing or dysfunctional antilipoperoxidant proteins. We questioned whether environmental pressures might have driven the evolution of exceptional natural product antilipoperoxidants in microorganisms that thrive in environments of extreme oxidative stress. We specifically sought to characterize the antilipoperoxidant activity of three highly atypical carotenoids, peridinin, synechoxanthin, and chlamydaxanthin. We synthesized each of these natural products utilizing an efficient and modular building block based approach. This strategy allowed for initial activity assays as well synthesis of isotopically labeled carotenoids and scale-up for animal experiments. We found that the atypical carotenoid peridinin is an exceptionally potent inhibitor of non-enzymatic bilayer lipid peroxidation in both chemically defined liposomes and primary human endothelial cells. Mechanistic investigation showed, as compared to astaxanthin, peridinin does not act through inhibition of lipid lateral diffusion nor does it have a higher inherent rate of radical quenching activity. SSNMR experiments with a synthesized isotopologue showed that the increased potency of peridinin is due to its increased propensity to embed within the lipid bilayer. That is, in contrast to the primarily extramembranous localization of the widely used but much less potent antilipoperoxidant astaxanthin, peridinin is completely embedded within and physically spans the hydrophobic core of POPC membranes, maximizing its concentration at the site of the targeted lipid peroxidation reactions. In a final set of experiments, we utilized peridinin to probe the role of lipid peroxidation in atherosclerosis and asthma. In primary human endothelial cells, we found that small molecule-mediated inhibition of bilayer lipid peroxidation blocks stress-induced monocyte-endothelial cell adhesion, a key step in atherogenesis. In contrast, in two different mouse models of acute asthma, our preliminary results suggest that lipid peroxidation does not drive the pathogenesis of asthma. We did not observe a consistent increase in oxidized lipids in these models, nor did peridinin have any measurable effect on the asthmatic phenotype. Further studies are required to understand the biodistribution of peridinin and evaluate lipid peroxidation in clinically relevant chronic mouse models of asthma. In conclusion, we have identified peridinin as a potent and membrane embedded inhibitor of lipid peroxidation with the potential to further probe the role of lipid peroxidation in a multitude of human diseases.","Submission published under a 24 month embargo labeled 'Closed Access', the embargo will last until 2020-05-01","The student, Adam Hill, accepted the attached license on 2018-03-13 at 09:06.","The student, Adam Hill, submitted this Dissertation for approval on 2018-03-13 at 09:33.","This Dissertation was approved for publication on 2018-03-13 at 16:47.","DSpace SAF Submission Ingestion Package generated from Vireo submission #12065 on 2018-08-31 at 17:25:14","Made available in DSpace on 2018-09-04T20:46:49Z (GMT). No. of bitstreams: 3 HILL-DISSERTATION-2018.pdf: 33224807 bytes, checksum: aefef5d4dd2153d62f8ec5f57e05872a (MD5) LICENSE.txt: 4206 bytes, checksum: ef6ce7874d42f876b15701ea24a4ee34 (MD5) PROQUEST_LICENSE.txt: 4552 bytes, checksum: d39fecade28b5022914a46809f86d527 (MD5) Previous issue date: 2018-03-13","Embargo set by: Seth Robbins for item 107346 Lift date: 2020-09-04T20:47:38Z Reason: Author requested closed access (OA after 2yrs) in Vireo ETD system","Embargo set by: Seth Robbins for item 107346 Lift date: 2020-09-04T20:50:11Z Reason: Author requested closed access (OA after 2yrs) in Vireo ETD system","Limited Restriction Lifted for Item 107346 on 2020-09-05T09:15:09Z."],"dc:format":["application/pdf"],"dc:identifier":["http://hdl.handle.net/2142/101261"],"dc:language":["en"],"dc:rights":["Copyright 2018 Adam Greschek Hill"],"dc:subject":["Chemistry","Biology","Chemical Biology","Lipid Oxidation","Antilipoperoxidant","Carotenoid","Natural Products","Solid-State Nuclear Magnetic Resonance","Atherosclerosis","Asthma","Astaxanthin","Chlamydaxanthin","Peridinin"],"dc:title":["Synthesis, biological activity and mechanism of atypical carotenoid antilipoperoxidants"],"dc:type":["text"],"thesis:degree_discipline":["Chemistry"],"thesis:degree_level":["Dissertation"],"thesis:degree_name":["Ph.D."],"thesis:institution_name":["University of Illinois at Urbana-Champaign"]},"updated_at":"2026-07-22T22:24:38Z"}